Position in EXEL
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$3,804,673
+$420,610 QoQ
Shares Held
69,926
-11.4% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#199
of 751 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Integrated Wealth Concepts LLC holds $51,111,338 across 302 Biotechnology names. EXEL ranks #3 (7.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMRN |
Biomarin Pharmaceutical Inc
|
152,216 | $8,709,799 | |
| 2 | INVA |
Innoviva, Inc.
|
350,575 | $7,961,558 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
69,926 | $3,804,673 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,994 | $3,474,129 | |
| 5 | DNLI |
Denali Therapeutics Inc.
|
102,241 | $2,629,638 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
6,692 | $2,014,492 | |
| 7 | INCY |
Incyte Corp
|
17,318 | $1,963,168 | |
| 8 | TLX |
Telix Pharmaceuticals Ltd
|
164,397 | $1,895,497 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,804,673 | 69,926 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $3,384,063 | 78,901 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $875,460 | 19,974 | Shares | Other | 2026-02-13 | |
| 2025-09-30 | $461,486 | 11,174 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $634,840 | 14,402 | Shares | Other | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||